A novel model of glioblastoma recurrence to identify therapeutic vulnerabilities
Abstract Glioblastoma remains incurable and recurs in all patients. Here we design and characterize a novel induced-recurrence model in which mice xenografted with primary patient-derived glioma initiating/stem cells (GIC) are treated with a therapeutic regimen closely recapitulating patient standar...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Springer Nature
2025-04-01
|
| Series: | EMBO Molecular Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1038/s44321-025-00237-z |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850221807403008000 |
|---|---|
| author | Sara Lucchini James G Nicholson Xinyu Zhang Jacob Househam Yau Mun Lim Maximilian Mossner Thomas O Millner Sebastian Brandner Trevor Graham Silvia Marino |
| author_facet | Sara Lucchini James G Nicholson Xinyu Zhang Jacob Househam Yau Mun Lim Maximilian Mossner Thomas O Millner Sebastian Brandner Trevor Graham Silvia Marino |
| author_sort | Sara Lucchini |
| collection | DOAJ |
| description | Abstract Glioblastoma remains incurable and recurs in all patients. Here we design and characterize a novel induced-recurrence model in which mice xenografted with primary patient-derived glioma initiating/stem cells (GIC) are treated with a therapeutic regimen closely recapitulating patient standard of care, followed by monitoring until tumours recur (induced recurrence patient-derived xenografts, IR-PDX). By tracking in vivo tumour growth, we confirm the patient specificity and initial efficacy of treatment prior to recurrence. Availability of longitudinally matched pairs of primary and recurrent GIC enabled patient-specific evaluation of the fidelity with which the model recapitulated phenotypes associated with the true recurrence. Through comprehensive multi-omic analyses, we show that the IR-PDX model recapitulates aspects of genomic, epigenetic, and transcriptional state heterogeneity upon recurrence in a patient-specific manner. The accuracy of the IR-PDX enabled both novel biological insights, including the positive association between glioblastoma recurrence and levels of ciliated neural stem cell-like tumour cells, and the identification of druggable patient-specific therapeutic vulnerabilities. This proof-of-concept study opens the possibility for prospective precision medicine approaches to identify target-drug candidates for treatment at glioblastoma recurrence. |
| format | Article |
| id | doaj-art-b3757cd1b9b2425fa9504e202117a67b |
| institution | OA Journals |
| issn | 1757-4684 |
| language | English |
| publishDate | 2025-04-01 |
| publisher | Springer Nature |
| record_format | Article |
| series | EMBO Molecular Medicine |
| spelling | doaj-art-b3757cd1b9b2425fa9504e202117a67b2025-08-20T02:06:35ZengSpringer NatureEMBO Molecular Medicine1757-46842025-04-011761325135410.1038/s44321-025-00237-zA novel model of glioblastoma recurrence to identify therapeutic vulnerabilitiesSara Lucchini0James G Nicholson1Xinyu Zhang2Jacob Househam3Yau Mun Lim4Maximilian Mossner5Thomas O Millner6Sebastian Brandner7Trevor Graham8Silvia Marino9Brain Tumour Research Centre, Blizard Institute, Faculty of Medicine and Dentistry, Queen Mary University LondonBrain Tumour Research Centre, Blizard Institute, Faculty of Medicine and Dentistry, Queen Mary University LondonBrain Tumour Research Centre, Blizard Institute, Faculty of Medicine and Dentistry, Queen Mary University LondonCentre for Evolution and Cancer, The Institute of Cancer ResearchDivision of Neuropathology, The National Hospital for Neurology and Neurosurgery, University College London Hospitals NHS Foundation Trust, and Department of Neurodegenerative Disease, Queen Square, Institute of Neurology, University College LondonCentre for Evolution and Cancer, The Institute of Cancer ResearchBrain Tumour Research Centre, Blizard Institute, Faculty of Medicine and Dentistry, Queen Mary University LondonDivision of Neuropathology, The National Hospital for Neurology and Neurosurgery, University College London Hospitals NHS Foundation Trust, and Department of Neurodegenerative Disease, Queen Square, Institute of Neurology, University College LondonCentre for Evolution and Cancer, The Institute of Cancer ResearchBrain Tumour Research Centre, Blizard Institute, Faculty of Medicine and Dentistry, Queen Mary University LondonAbstract Glioblastoma remains incurable and recurs in all patients. Here we design and characterize a novel induced-recurrence model in which mice xenografted with primary patient-derived glioma initiating/stem cells (GIC) are treated with a therapeutic regimen closely recapitulating patient standard of care, followed by monitoring until tumours recur (induced recurrence patient-derived xenografts, IR-PDX). By tracking in vivo tumour growth, we confirm the patient specificity and initial efficacy of treatment prior to recurrence. Availability of longitudinally matched pairs of primary and recurrent GIC enabled patient-specific evaluation of the fidelity with which the model recapitulated phenotypes associated with the true recurrence. Through comprehensive multi-omic analyses, we show that the IR-PDX model recapitulates aspects of genomic, epigenetic, and transcriptional state heterogeneity upon recurrence in a patient-specific manner. The accuracy of the IR-PDX enabled both novel biological insights, including the positive association between glioblastoma recurrence and levels of ciliated neural stem cell-like tumour cells, and the identification of druggable patient-specific therapeutic vulnerabilities. This proof-of-concept study opens the possibility for prospective precision medicine approaches to identify target-drug candidates for treatment at glioblastoma recurrence.https://doi.org/10.1038/s44321-025-00237-zGlioblastomaRecurrenceMouse ModelPrecision-medicineCilia |
| spellingShingle | Sara Lucchini James G Nicholson Xinyu Zhang Jacob Househam Yau Mun Lim Maximilian Mossner Thomas O Millner Sebastian Brandner Trevor Graham Silvia Marino A novel model of glioblastoma recurrence to identify therapeutic vulnerabilities EMBO Molecular Medicine Glioblastoma Recurrence Mouse Model Precision-medicine Cilia |
| title | A novel model of glioblastoma recurrence to identify therapeutic vulnerabilities |
| title_full | A novel model of glioblastoma recurrence to identify therapeutic vulnerabilities |
| title_fullStr | A novel model of glioblastoma recurrence to identify therapeutic vulnerabilities |
| title_full_unstemmed | A novel model of glioblastoma recurrence to identify therapeutic vulnerabilities |
| title_short | A novel model of glioblastoma recurrence to identify therapeutic vulnerabilities |
| title_sort | novel model of glioblastoma recurrence to identify therapeutic vulnerabilities |
| topic | Glioblastoma Recurrence Mouse Model Precision-medicine Cilia |
| url | https://doi.org/10.1038/s44321-025-00237-z |
| work_keys_str_mv | AT saralucchini anovelmodelofglioblastomarecurrencetoidentifytherapeuticvulnerabilities AT jamesgnicholson anovelmodelofglioblastomarecurrencetoidentifytherapeuticvulnerabilities AT xinyuzhang anovelmodelofglioblastomarecurrencetoidentifytherapeuticvulnerabilities AT jacobhouseham anovelmodelofglioblastomarecurrencetoidentifytherapeuticvulnerabilities AT yaumunlim anovelmodelofglioblastomarecurrencetoidentifytherapeuticvulnerabilities AT maximilianmossner anovelmodelofglioblastomarecurrencetoidentifytherapeuticvulnerabilities AT thomasomillner anovelmodelofglioblastomarecurrencetoidentifytherapeuticvulnerabilities AT sebastianbrandner anovelmodelofglioblastomarecurrencetoidentifytherapeuticvulnerabilities AT trevorgraham anovelmodelofglioblastomarecurrencetoidentifytherapeuticvulnerabilities AT silviamarino anovelmodelofglioblastomarecurrencetoidentifytherapeuticvulnerabilities AT saralucchini novelmodelofglioblastomarecurrencetoidentifytherapeuticvulnerabilities AT jamesgnicholson novelmodelofglioblastomarecurrencetoidentifytherapeuticvulnerabilities AT xinyuzhang novelmodelofglioblastomarecurrencetoidentifytherapeuticvulnerabilities AT jacobhouseham novelmodelofglioblastomarecurrencetoidentifytherapeuticvulnerabilities AT yaumunlim novelmodelofglioblastomarecurrencetoidentifytherapeuticvulnerabilities AT maximilianmossner novelmodelofglioblastomarecurrencetoidentifytherapeuticvulnerabilities AT thomasomillner novelmodelofglioblastomarecurrencetoidentifytherapeuticvulnerabilities AT sebastianbrandner novelmodelofglioblastomarecurrencetoidentifytherapeuticvulnerabilities AT trevorgraham novelmodelofglioblastomarecurrencetoidentifytherapeuticvulnerabilities AT silviamarino novelmodelofglioblastomarecurrencetoidentifytherapeuticvulnerabilities |